Correlation of Non-tumoral Liver Dose with Treatment-Related Adverse Events in Patients with Hepatocellular Carcinoma Treated with Glass-Based Yttrium-90 Radioembolization

[1]  D. Sze,et al.  A global evaluation of advanced dosimetry in transarterial radioembolization of hepatocellular carcinoma with Yttrium-90: the TARGET study , 2022, European Journal of Nuclear Medicine and Molecular Imaging.

[2]  D. Schuster,et al.  Role of Resin Microsphere Y90 Dosimetry in Predicting Objective Tumor Response, Survival and Treatment Related Toxicity in Surgically Unresectable Colorectal Liver Metastasis: A Retrospective Single Institution Study , 2021, Cancers.

[3]  S. Sheikh,et al.  Prognostic factors of unresectable hepatocellular carcinoma treated with yttrium-90 radioembolization: results from a large cohort over 13 years at a single center. , 2021, Journal of gastrointestinal oncology.

[4]  K. Knešaurek.  An estimate of 90Y dosimetry for bremsstrahlung SPECT/CT imaging in liver therapy with 90Y microspheres. , 2021, European journal of radiology.

[5]  D. Schuster,et al.  Tumor-to-Normal Ratio Relationship between Planning Technetium-99 Macroaggregated Albumin and Posttherapy Yttrium-90 Bremsstrahlung SPECT/CT. , 2021, Journal of vascular and interventional radiology : JVIR.

[6]  D. Sze,et al.  International recommendations for personalised selective internal radiation therapy of primary and metastatic liver diseases with yttrium-90 resin microspheres , 2021, European Journal of Nuclear Medicine and Molecular Imaging.

[7]  T. de Baère,et al.  Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. , 2020, The lancet. Gastroenterology & hepatology.

[8]  D. Rubello,et al.  Selective internal radiation therapy of hepatic tumors: Morphologic and functional imaging for voxel-based computer-aided dosimetry , 2020, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[9]  D. Schuster,et al.  Comparison of Tc-99m MAA Planar Versus SPECT/CT Imaging for Lung Shunt Fraction Evaluation Prior to Y-90 Radioembolization: Are We Overestimating Lung Shunt Fraction? , 2020, CardioVascular and Interventional Radiology.

[10]  R. Salem,et al.  Correlation of Y90-absorbed radiation dose to pathological necrosis in hepatocellular carcinoma: confirmatory multicenter analysis in 45 explants , 2020, European Journal of Nuclear Medicine and Molecular Imaging.

[11]  Versione,et al.  Common Terminology Criteria for Adverse Events , 2020, Definitions.

[12]  W. Sensakovic,et al.  SPECT/CT image‐based dosimetry for Yttrium‐90 radionuclide therapy: Application to treatment response , 2018, Journal of applied clinical medical physics.

[13]  Keith T. Chan,et al.  Hepatotoxic Dose Thresholds by Positron-Emission Tomography After Yttrium-90 Radioembolization of Liver Tumors: A Prospective Single-Arm Observational Study , 2018, CardioVascular and Interventional Radiology.

[14]  Y. Rolland,et al.  High impact of macroaggregated albumin‐based tumour dose on response and overall survival in hepatocellular carcinoma patients treated with 90Y‐loaded glass microsphere radioembolization , 2016, Liver international : official journal of the International Association for the Study of the Liver.

[15]  A. Nelson,et al.  Evaluation of a voxel-based yttrium-90 (Y-90) dose calculation method for Bremsstrahlung SPECT using a liver phantom , 2016 .

[16]  D. Schuster,et al.  (90)Y Radioembolization: Multimodality Imaging Pattern Approach with Angiographic Correlation for Optimized Target Therapy Delivery. , 2015, Radiographics : a review publication of the Radiological Society of North America, Inc.

[17]  V. Mazzaferro,et al.  Radioembolization of hepatocarcinoma with 90Y glass microspheres: development of an individualized treatment planning strategy based on dosimetry and radiobiology , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[18]  J. Ertle,et al.  In intermediate stage hepatocellular carcinoma: radioembolization with yttrium 90 or chemoembolization? , 2015, Liver international : official journal of the International Association for the Study of the Liver.

[19]  S. Minoshima,et al.  Comparison of positron emission tomography and bremsstrahlung imaging to detect particle distribution in patients undergoing yttrium-90 radioembolization for large hepatocellular carcinomas or associated portal vein thrombosis. , 2013, Journal of vascular and interventional radiology : JVIR.

[20]  T. Therneau,et al.  Efficacy and Safety of Transarterial Radioembolization Versus Chemoembolization in Patients With Hepatocellular Carcinoma , 2013, CardioVascular and Interventional Radiology.

[21]  K. Boudjema,et al.  Boosted selective internal radiation therapy with 90Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: a new personalized promising concept , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[22]  N. Obuchowski,et al.  Comparative analysis of the safety and efficacy of transcatheter arterial chemoembolization and yttrium-90 radioembolization in patients with unresectable hepatocellular carcinoma. , 2011, Journal of vascular and interventional radiology : JVIR.

[23]  A. Benson,et al.  Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. , 2011, Gastroenterology.

[24]  J. Ertle,et al.  Radioembolization with yttrium‐90 glass microspheres in hepatocellular carcinoma: European experience on safety and long‐term survival , 2010, Hepatology.

[25]  M. Mulcahy,et al.  Complications following radioembolization with yttrium-90 microspheres: a comprehensive literature review. , 2009, Journal of vascular and interventional radiology : JVIR.

[26]  Wesley E. Bolch,et al.  MIRD Pamphlet No. 21: A Generalized Schema for Radiopharmaceutical Dosimetry—Standardization of Nomenclature , 2009, Journal of Nuclear Medicine.

[27]  M. Bloomston,et al.  Yttrium-90 microsphere induced gastrointestinal tract ulceration , 2008, World journal of surgical oncology.

[28]  E. McFadden,et al.  Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.

[29]  W E Bolch,et al.  MIRD pamphlet No. 17: the dosimetry of nonuniform activity distributions--radionuclide S values at the voxel level. Medical Internal Radiation Dose Committee. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.